Performance status score: do patients and their oncologists agree?

Sarah P. Blagden(Churchill Hospital), David Gilligan(University of Cambridge), Linda Sharples(University of London), Susan C. Charman(MRC Biostatistics Unit), L. Magee(Papworth Hospital)

British Journal of Cancer

September 1, 2003

10.1038/sj.bjc.6601231

Cited by 222

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Acute vascular effects of estrogen in postmenopausal women.

|Circulation|1994|555

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

|Clinical Cancer Research|2011|168